ArticleThe Journal of biological chemistry2026
The crystal structure of the activin B:Fst288 complex and computational insights into the broad antagonistic activity and specificity of follistatin.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
Members of the transforming growth factor-β (TGF-β) family regulate essential biological processes, and their activity is tightly controlled by extracellular antagonists like follistatin 288 (Fst288). While Fst288 potently inhibits several ligands, including activins A and B, GDF8, and GDF11, the structural basis for its interaction with activin B (ActB) has remained largely uncharacterized. This lack of data has limited our understanding of how Fst288 achieves such broad inhibitory activity while maintaining ligand-specific selectivity. In this study, we resolved the crystal structure of the ActB:Fst288 complex at 2.7 Å resolution. Our findings reveal that while Fst288 utilizes a conserved receptor-blocking mechanism, ActB engages the antagonist through a modified structural mode. Most notably, the fingertips of ActB form direct, unique contacts with the third follistatin domain (FSD3). This interaction disrupts the intermolecular head-to-tail cooperativity typically seen in Fst288 dimers, shifting the stabilization of the complex toward individual ligand-domain affinities. Computational analysis supports a model where ActB relies more on direct contacts with Fst288, whereas ActA relies on the intermolecular head-to-tail Fst288 interactions. Further computational analysis indicates ActB is more flexible than ActA and GDF8. These results suggest that Fst288's broad potency arises from a dynamic interplay between ligand flexibility and antagonist conformational plasticity that can accommodate different ligand surfaces. By elucidating unique characteristics of the ActB:Fst288 interface, this study deepens the understanding of ligand selectivity and provides a framework for the rational design of targeted TGF-β antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.